IGF2BP1 and renal cell carcinoma: Knockdown of THOR expression level via applying a CRISPR/Cas9 genome editing system could suppress the expression levels of IGF2BP1-regulated genes, containing IGF2, Myc, and GLI1, and thereby inhibiting proliferation and viability of RCC cells.